CA2370413A1 - Hla binding peptides and their uses - Google Patents

Hla binding peptides and their uses Download PDF

Info

Publication number
CA2370413A1
CA2370413A1 CA002370413A CA2370413A CA2370413A1 CA 2370413 A1 CA2370413 A1 CA 2370413A1 CA 002370413 A CA002370413 A CA 002370413A CA 2370413 A CA2370413 A CA 2370413A CA 2370413 A1 CA2370413 A1 CA 2370413A1
Authority
CA
Canada
Prior art keywords
peptide
peptides
epitope
hla
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370413A
Other languages
English (en)
French (fr)
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370413A1 publication Critical patent/CA2370413A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002370413A 1999-06-29 2000-06-28 Hla binding peptides and their uses Abandoned CA2370413A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14142299P 1999-06-29 1999-06-29
US60/141,422 1999-06-29
PCT/US2000/017842 WO2001000225A1 (en) 1999-06-29 2000-06-28 Hla binding peptides and their uses

Publications (1)

Publication Number Publication Date
CA2370413A1 true CA2370413A1 (en) 2001-01-04

Family

ID=22495620

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370413A Abandoned CA2370413A1 (en) 1999-06-29 2000-06-28 Hla binding peptides and their uses

Country Status (6)

Country Link
EP (2) EP1189624A4 (enExample)
JP (1) JP2003535024A (enExample)
AT (1) ATE512666T1 (enExample)
AU (1) AU5898400A (enExample)
CA (1) CA2370413A1 (enExample)
WO (1) WO2001000225A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20040096445A1 (en) * 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
CA2377525A1 (en) * 1999-07-19 2001-03-29 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
EP1230268B1 (en) 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2001041787A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
WO2001074847A2 (en) * 2000-03-30 2001-10-11 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
CA2407104A1 (en) * 2000-05-12 2001-11-22 Northwest Biotherapeutics, Inc. Method to increase class i presentation of exogenous antigens by human dendritic cells
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
CA2464239C (en) 2001-10-23 2016-07-12 Psma Development Company, L.L.C. Psma antibodies and protein multimers
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
PL1620456T3 (pl) * 2003-04-18 2014-06-30 Ose Pharma Int Sa Peptydy antygenu związanego z nowotworem HLA-A2 i kompozycje
TWI262192B (en) * 2003-07-01 2006-09-21 Univ Nat Taiwan Labeling peptide for nasopharyngeal carcinoma (NPC) cells
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
JP2007277092A (ja) * 2004-06-17 2007-10-25 Univ Kurume 前立腺関連抗原由来ｈｌａ−ａ２結合性ペプチド
EP1840133A1 (en) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. New immunomodulating oligopeptides
US9511134B2 (en) 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US8282938B2 (en) 2008-11-28 2012-10-09 National Institute Of Infectious Diseases Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CA3197245A1 (en) * 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
WO2015130488A2 (en) 2014-02-28 2015-09-03 Immunotope, Inc. Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
IL302102A (en) 2015-05-20 2023-06-01 Dana Farber Cancer Inst Inc shared neoantigens
CN117801069A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
CN110022893B (zh) * 2016-10-07 2023-12-29 恩特罗姆公司 用于癌症疗法的免疫原性化合物
WO2018126060A1 (en) 2016-12-28 2018-07-05 Invvax, Inc. Influenza vaccines
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN111093691A (zh) 2017-04-03 2020-05-01 内恩疗法公司 蛋白质抗原及其用途
NL2019814B1 (en) * 2017-10-26 2019-05-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Methods for producing a MHC multimer.
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
FI3773689T3 (fi) 2018-04-11 2023-01-31 Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
US12246067B2 (en) 2018-06-19 2025-03-11 Biontech Us Inc. Neoantigens and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE466869T1 (de) * 1993-03-05 2010-05-15 Epimmune Inc Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden
EP0726758B1 (en) * 1993-08-02 2002-11-06 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
EP1012238A4 (en) * 1997-01-31 2003-03-05 Epimmune Inc PEPTIDES AND ANTIQUE PRESENTING CELLS LOADED WITH PEPTIDES FOR THE ACTIVATION OF CYTOTOXIC T CELLS
CA2400215A1 (en) * 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses

Also Published As

Publication number Publication date
EP1917970B1 (en) 2011-06-15
AU5898400A (en) 2001-01-31
EP1917970A3 (en) 2008-09-24
ATE512666T1 (de) 2011-07-15
EP1189624A1 (en) 2002-03-27
WO2001000225A1 (en) 2001-01-04
EP1917970A2 (en) 2008-05-07
EP1189624A4 (en) 2005-02-23
JP2003535024A (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
EP1917970B1 (en) Hla binding peptides and their uses
US7252829B1 (en) HLA binding peptides and their uses
AU725550B2 (en) HLA binding peptides and their uses
EP1911461B1 (en) HLA class I and II binding peptides and their uses
US9340577B2 (en) HLA binding motifs and peptides and their uses
CA2248667C (en) Hla-a2.1 binding peptides and their uses
US20100068228A1 (en) Inducing Cellular Immune Responses to Hepatitis B Virus Using Peptide and Nucleic Acid Compositions
EP1263775A1 (en) Hla binding peptides and their uses
US20020098197A1 (en) Hla binding peptides and their uses
US20020177694A1 (en) Hla binding peptides and their uses
EP1089757B1 (en) Hla binding peptides and their uses
CA2420225A1 (en) Hla-a2.1 binding peptides and their uses
EP1320377B1 (en) Hla binding peptides and their uses
CA2421448A1 (en) Hla binding peptides and their uses
AU4754899A (en) HLA Binding peptides and their uses
KR20030036139A (ko) Ｈｌａ 결합 펩티드 및 이의 용도

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued